Takeda Pharmaceutical Initiates Phase II Clinical Test For Compound TAK-491 For Treatment Of Hypertension

Main Category: Hypertension
Also Included In: Clinical Trials / Drug Trials
Article Date: 17 Jul 2006 - 23:00 PDT

email to a friend   printer friendly   opinions  

Takeda Pharmaceutical has announced that its investigational compound TAK-491 has entered into the Phase II clinical stage in the US and Europe.

An angiotensin receptor blocker (ARB) discovered by Takeda, TAK-491 helps lower blood pressure by suppressing the action of vasopressor hormone Angiotensin II.

The new compound is superior to the conventional ARB in that it demonstrates stronger anti-hypertension action, improves the insulin resistance, and decreases proteinuria.

TAK-491 is expected to support the expansion of the US diabetic franchise of Actos (generic name: pioglitazone HCI) into lifestyle-related diseases. Also, the new drug will help the company increase its presence in the European cardiovascular market along with Candesartan, another drug found by Takeda which treats hypertension.

By Aki Tsukioka, JCN Staff Writer

Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.

JCN

• Additional
• References
• Citations